Hao Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hao Wu has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Frederic Buono
Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
7 shared publications Jon C. Lorenz
Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
4 shared publications- Nizar Haddad
Chemical Development US, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd, Ridgefield, Connecticut 06877, United States
4 shared publications - Yongda Zhang
Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
3 shared publications - Zhen Lei
Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
3 shared publications - Binh Khanh Mai
Department of Chemistry, University of Pittsburgh, Pittsburgh, USA
2 shared publications
Latest Publications
- 1 July 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (7) , 1822-1830
Biocatalytic Synthesis of (R)-3-Aminotetrahydropyran through a Direct Transamination at Kilogram Scale
- 1 July 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (7) , 1822-1830
Biocatalytic Synthesis of (R)-3-Aminotetrahydropyran through a Direct Transamination at Kilogram Scale
- Open Access
- 9 June 2025
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 15 (12) , 10780-10794
The Evolving Landscape of Industrial Biocatalysis in Perspective from the ACS Green Chemistry Institute Pharmaceutical Roundtable
- 9 June 2025
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 15 (12) , 10780-10794
Open AccessThe Evolving Landscape of Industrial Biocatalysis in Perspective from the ACS Green Chemistry Institute Pharmaceutical Roundtable
- 27 March 2025
- Published by Royal Society of Chemistry (RSC) in Reaction Chemistry & Engineering
- Vol. 10 (7) , 1508-1516
Synthesis of a spiroketone intermediate featuring a green and sustainable telescoped flow process
A telescoped flow process was implemented for synthesizing a chiral spiroketone, a pivotal building block of several active pharmaceutical ingredients. This process combined a ring closing metathesis step and a hydrogenation step using one single catalyst (Hoveyda–Grubbs 2nd generation catalyst). This innovative approach offers substantial benefits including cost savings, enhanced throughput with adaptable demo-scale devices, real-time reaction monitoring via process analytical technology, elimination of laborious intermediate separation, decreased process mass intensity, and streamlined unit operations. Notably, the developed telescoped flow process utilizes one single catalyst with a significantly reduced loading, resulting in a remarkable 70% saving on process cost and a 60% decrease in PMI compared to the original batch procedure.
- 27 March 2025
- Published by Royal Society of Chemistry (RSC) in Reaction Chemistry & Engineering
- Vol. 10 (7) , 1508-1516
Synthesis of a spiroketone intermediate featuring a green and sustainable telescoped flow process
A telescoped flow process was implemented for synthesizing a chiral spiroketone, a pivotal building block of several active pharmaceutical ingredients. This process combined a ring closing metathesis step and a hydrogenation step using one single catalyst (Hoveyda–Grubbs 2nd generation catalyst). This innovative approach offers substantial benefits including cost savings, enhanced throughput with adaptable demo-scale devices, real-time reaction monitoring via process analytical technology, elimination of laborious intermediate separation, decreased process mass intensity, and streamlined unit operations. Notably, the developed telescoped flow process utilizes one single catalyst with a significantly reduced loading, resulting in a remarkable 70% saving on process cost and a 60% decrease in PMI compared to the original batch procedure.
- 24 March 2025
- Published by American Chemical Society (ACS) in ACS Sustainable Chemistry & Engineering
- Vol. 13 (13) , 5009-5018
Biocatalytic Reduction of Heterocyclic Imines in Continuous Flow with Immobilized Enzymes
- 24 March 2025
- Published by American Chemical Society (ACS) in ACS Sustainable Chemistry & Engineering
- Vol. 13 (13) , 5009-5018
Biocatalytic Reduction of Heterocyclic Imines in Continuous Flow with Immobilized Enzymes
- 9 August 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (9) , 3524-3544
Recent Advances in Nonprecious Metal Catalysis
- 9 August 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (9) , 3524-3544
Recent Advances in Nonprecious Metal Catalysis
- 2 August 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (8) , 3404-3413
G-EnzyBeads for Biocatalysis Screening Facilitated by Volumetric Dosing
- 2 August 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (8) , 3404-3413
G-EnzyBeads for Biocatalysis Screening Facilitated by Volumetric Dosing
- Top Cited Papers
- 26 April 2024
- Published by Springer Nature in Nature Synthesis
- Vol. 3 (8) , 967-975
Biocatalytic enantioselective C(sp3)–H fluorination enabled by directed evolution of non-haem iron enzymes
Due to the scarcity of C–F bond-forming enzymatic reactions in nature and the contrasting prevalence of organofluorine moieties in bioactive compounds, developing biocatalytic fluorination reactions represents a pre-eminent challenge in enzymology, biocatalysis and synthetic biology. Additionally, catalytic enantioselective C(sp3)–H fluorination remains a challenging problem facing synthetic chemists. Although many non-haem iron halogenases have been discovered to promote C(sp3)–H halogenation reactions, efforts to convert these iron halogenases to fluorinases have remained unsuccessful. Here we report the development of an enantioselective C(sp3)–H fluorination reaction, catalysed by a plant-derived non-haem enzyme 1-aminocyclopropane-1-carboxylic acid oxidase (ACCO), which is repurposed for radical rebound fluorination. Directed evolution afforded a C(sp3)–H fluorinating enzyme ACCOCHF displaying 200-fold higher activity, substantially improved chemoselectivity and excellent enantioselectivity, converting a range of substrates into enantioenriched organofluorine products. Notably, almost all the beneficial mutations were found to be distal to the iron centre, underscoring the importance of substrate tunnel engineering in non-haem iron biocatalysis. Computational studies reveal that the radical rebound step with the Fe(III)–F intermediate has a low activation barrier of 3.4 kcal mol−1 and is kinetically facile.
- 26 April 2024
- Published by Springer Nature in Nature Synthesis
- Vol. 3 (8) , 967-975
Top Cited PapersBiocatalytic enantioselective C(sp3)–H fluorination enabled by directed evolution of non-haem iron enzymes
Due to the scarcity of C–F bond-forming enzymatic reactions in nature and the contrasting prevalence of organofluorine moieties in bioactive compounds, developing biocatalytic fluorination reactions represents a pre-eminent challenge in enzymology, biocatalysis and synthetic biology. Additionally, catalytic enantioselective C(sp3)–H fluorination remains a challenging problem facing synthetic chemists. Although many non-haem iron halogenases have been discovered to promote C(sp3)–H halogenation reactions, efforts to convert these iron halogenases to fluorinases have remained unsuccessful. Here we report the development of an enantioselective C(sp3)–H fluorination reaction, catalysed by a plant-derived non-haem enzyme 1-aminocyclopropane-1-carboxylic acid oxidase (ACCO), which is repurposed for radical rebound fluorination. Directed evolution afforded a C(sp3)–H fluorinating enzyme ACCOCHF displaying 200-fold higher activity, substantially improved chemoselectivity and excellent enantioselectivity, converting a range of substrates into enantioenriched organofluorine products. Notably, almost all the beneficial mutations were found to be distal to the iron centre, underscoring the importance of substrate tunnel engineering in non-haem iron biocatalysis. Computational studies reveal that the radical rebound step with the Fe(III)–F intermediate has a low activation barrier of 3.4 kcal mol−1 and is kinetically facile.
- Open Access
- 28 March 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Biocatalytic enantioselective C(sp3)–H fluorination enabled by directed evolution of nonhemeFe enzymes
Due to the scarcity of C–F bond forming enzymatic activities in nature and the contrasting ubiquity of organofluorine moieties in bioactive compounds, developing new biocatalytic fluorination reactions represents a preeminent challenge in enzymology, biocatalysis, and synthetic biology. Additionally, catalytic asymmetric C(sp3)–H fluorination remains a challenging problem facing synthetic chemists. Although many nonheme Fe halogenases have been discovered to promote C(sp3)–H halogenation reactions, to date, efforts to convert these Fe halogenases to fluorinases have remained unsuccessful. We repurposed a plant-derived natural nonheme enzyme 1-aminocyclopropane-1-carboxylic acid oxidase (ACCO) to catalyze unnatural enantioselective C(sp3)–H fluorination via a radical rebound mechanism. Directed evolution afforded C–H fluorinating enzyme ACCOCHF displaying 200-fold higher activity, substantially improved chemoselectivity and excellent enantioselectivity, converting a range of substrates into enantioenriched organofluorine products. Notably, almost all the beneficial mutations were found to be distal to the Fe centre, underscoring the importance of substrate tunnel engineering in nonheme Fe biocatalysis. Computational studies revealed that the radical rebound step with the Fe(III)–F intermediate has an exceedingly low activation barrier of 3.4 kcal/mol, highlighting a new avenue to expand the catalytic repertoire of enzymes to encompass asymmetric C–F bond formation.
- 28 March 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessBiocatalytic enantioselective C(sp3)–H fluorination enabled by directed evolution of nonhemeFe enzymes
Due to the scarcity of C–F bond forming enzymatic activities in nature and the contrasting ubiquity of organofluorine moieties in bioactive compounds, developing new biocatalytic fluorination reactions represents a preeminent challenge in enzymology, biocatalysis, and synthetic biology. Additionally, catalytic asymmetric C(sp3)–H fluorination remains a challenging problem facing synthetic chemists. Although many nonheme Fe halogenases have been discovered to promote C(sp3)–H halogenation reactions, to date, efforts to convert these Fe halogenases to fluorinases have remained unsuccessful. We repurposed a plant-derived natural nonheme enzyme 1-aminocyclopropane-1-carboxylic acid oxidase (ACCO) to catalyze unnatural enantioselective C(sp3)–H fluorination via a radical rebound mechanism. Directed evolution afforded C–H fluorinating enzyme ACCOCHF displaying 200-fold higher activity, substantially improved chemoselectivity and excellent enantioselectivity, converting a range of substrates into enantioenriched organofluorine products. Notably, almost all the beneficial mutations were found to be distal to the Fe centre, underscoring the importance of substrate tunnel engineering in nonheme Fe biocatalysis. Computational studies revealed that the radical rebound step with the Fe(III)–F intermediate has an exceedingly low activation barrier of 3.4 kcal/mol, highlighting a new avenue to expand the catalytic repertoire of enzymes to encompass asymmetric C–F bond formation.
- 22 February 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (3) , 652-660
Green Chemistry Articles of Interest to the Pharmaceutical Industry
- 22 February 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (3) , 652-660
Green Chemistry Articles of Interest to the Pharmaceutical Industry